Halosin1.87 gm/ml

Halosin 1.87 gm/ml is a volatile anaesthetic which is suitable for the induction and maintenance of anaesthesia for all types of surgery and in patients of all ages.

General (Inhalation) anesthetics

When inhaled, Halosin 1.87 gm/ml is absorbed through the alveoli into the bloodstream. In the bloodstream, Halosin 1.87 gm/ml circulates through the body to the principal site of action, the brain. Here Halosin 1.87 gm/ml causes a progressive depression of the central nervous system, beginning with the higher centers (cerebral cortex) and spreading to the vital centers in the medulla. This depression is reversible. However, its mode of action, like all anaesthetic agents, is unknown.Halosin 1.87 gm/ml has a relatively low solubility in blood and therefore alveoli/blood concentrations equilibrate rapidly. The triexponential decline in Halosin 1.87 gm/ml blood concentrations following the end of administration is thought to represent distribution into three compartments; the vessel rich group (brain/heart/liver), the musculature and adipose tissue. Approximately 80% of the inhaled Halosin 1.87 gm/ml is eliminated unchanged by the lungs. The remaining 20% is metabolized in the liver by oxidative and under hypoxic conditions, reductive pathways. The main metabolites are trifluoroacetic acid, bromide and chloride salts (via the oxidative pathway) and fluoride salts (via the reductive pathway). The concentrations of metabolites peak 24 hours post-operatively and are eliminated by renal excretion during the following week.

A number of anaesthetic vaporisers specially designed for use with Halosin 1.87 gm/ml are available. Open, semi-open, semi-closed and closed circuit systems have all been used with good results.For induction of anaesthesia: Adult: A concentration of 2-4% Halosin 1.87 gm/ml in Oxygen or Nitrous Oxide may be used. Children: A concentration of 1.5-2% Halosin 1.87 gm/ml in Oxygen or Nitrous Oxide is used. For maintenance of anaesthesia: Adults and children: A concentration of 0.5-2% is usually required for maintenance of anaesthesia. The lower concentration is usually most suitable for elderly patients.

A number of anaesthetic vaporisers specially designed for use with Halosin 1.87 gm/ml are available. Open, semi-open, semi-closed and closed circuit systems have all been used with good results.For induction of anaesthesia: Adult: A concentration of 2-4% Halosin 1.87 gm/ml in Oxygen or Nitrous Oxide may be used. Children: A concentration of 1.5-2% Halosin 1.87 gm/ml in Oxygen or Nitrous Oxide is used. For maintenance of anaesthesia: Adults and children: A concentration of 0.5-2% is usually required for maintenance of anaesthesia. The lower concentration is usually most suitable for elderly patients.

Increased risk of ventricular dysrhythmias with epinephrine. Increased risk of malignant hyperthermia with suxamethonium. Prolonged recovery from anaesth with concurrent use of ketamine for induction. May potentiate response to non-depolarising muscle relaxants, hypotensive agents (e.g. hexamethonium bromide, trimetaphan camsilate).

Halosin 1.87 gm/ml can induce liver damage; however, the incidence of severe liver damage (jaundice, which may lead to hepatic failure as a consequence of massive hepatic cell necrosis) is unknown. The risk of developing hepatic failure appears to be increased by repeated exposure. Although short intervals of time between exposures are likely to increase the risk of hepatotoxicity, even long intervals between exposures maynot eliminate the risks, since some patients have developed severe reactions following Halosin 1.87 gm/ml given many years after the previous exposures. On the information which is available at the present time, it is advised that the followingprecautions be taken A careful anaesthetic history should be taken prior to use, to determine previous exposure and previous reactions following Halosin 1.87 gm/ml anaesthesia. Repeated exposure to Halosin 1.87 gm/ml within a period of at least 3 months should be avoided unless there are overriding clinical circumstances. History of unexplained jaundice and pyrexia in a patient following exposure to Halosin 1.87 gm/ml is a contraindication to its future use in that patient unless absolutely essential. Patients should be informed if they have developed a reaction possibly related to Halosin 1.87 gm/ml anaesthesia; such patients should be provided with a medical alert card stating the problem.

Post-op nausea, vomiting, and shivering; resp depression, hypotension, skeletal muscle relaxation, bradycardia.

Category C: Although the data from experimental investigations in animals cannot be directly related to man, it would be prudent to avoid general anaesthesia with inhalation agents during early pregnancy, except where such use is essential.Lactation: There are no well controlled studies with Halosin 1.87 gm/ml in lactating women. Halosin 1.87 gm/ml has been detected in breast milk of lactating women, but the effect of Halosin 1.87 gm/ml on breast feed neonates has not been established. However, Halosin 1.87 gm/ml has been in wide use for over 30 years without apparent ill consequence

Caution should be exercised during administration of adrenaline to patients anaesthetised with Halosin 1.87 gm/ml as dysrhythmias may be precipitated. For this reason the dose of adrenaline should be restricted and beta-receptor antagonists administered if necessary. Ensure adequate room ventilation when Halosin 1.87 gm/ml is being used. Keep the concentration of Halosin 1.87 gm/ml in air as low as possible.Effect on ability to drive or operate machinery: Patients should be advised that performance at skilled tasks, such as driving and operating machinery, may be impaired for some time after general anaesthesia.Accidental ingestion: Cases of ingestion must be treated symptomatically.

Bottles of Halosin 1.87 gm/ml must be securely closed and stored in a cool dry place, protected from light. Halosin 1.87 gm/ml must be kept in the original container until immediately prior to its use.Whilst in the liquid phase, Halosin 1.87 gm/ml must not be diluted or contaminated; however, in the vapour phase it may be administered together with Oxygen or a mixture of Nitrous Oxide and Oxygen.

General (Inhalation) anesthetics

When inhaled, Halosin 1.87 gm/ml is absorbed through the alveoli into the bloodstream. In the bloodstream, Halosin 1.87 gm/ml circulates through the body to the principal site of action, the brain. Here Halosin 1.87 gm/ml causes a progressive depression of the central nervous system, beginning with the higher centers (cerebral cortex) and spreading to the vital centers in the medulla. This depression is reversible. However, its mode of action, like all anaesthetic agents, is unknown.Halosin 1.87 gm/ml has a relatively low solubility in blood and therefore alveoli/blood concentrations equilibrate rapidly. The triexponential decline in Halosin 1.87 gm/ml blood concentrations following the end of administration is thought to represent distribution into three compartments; the vessel rich group (brain/heart/liver), the musculature and adipose tissue. Approximately 80% of the inhaled Halosin 1.87 gm/ml is eliminated unchanged by the lungs. The remaining 20% is metabolized in the liver by oxidative and under hypoxic conditions, reductive pathways. The main metabolites are trifluoroacetic acid, bromide and chloride salts (via the oxidative pathway) and fluoride salts (via the reductive pathway). The concentrations of metabolites peak 24 hours post-operatively and are eliminated by renal excretion during the following week.

Category C: Although the data from experimental investigations in animals cannot be directly related to man, it would be prudent to avoid general anaesthesia with inhalation agents during early pregnancy, except where such use is essential.Lactation: There are no well controlled studies with Halosin 1.87 gm/ml in lactating women. Halosin 1.87 gm/ml has been detected in breast milk of lactating women, but the effect of Halosin 1.87 gm/ml on breast feed neonates has not been established. However, Halosin 1.87 gm/ml has been in wide use for over 30 years without apparent ill consequence